Attention-Deficit/Hyperactivity Disorder (ADHD)

Adult ADHD is not about being hyper. It usually shows up as chronic difficulty starting tasks, sustaining attention on things that are not intrinsically interesting, finishing what was started, holding a thought in working memory long enough to act on it, and regulating emotion when a task is frustrating. Many adults compensated for years and only feel the full weight when life adds load: a demanding job, a new baby, graduate school, or a chronic stressor. The diagnosis requires symptoms that began in childhood and that impair function across more than one domain.

Adult ADHD is a clinical diagnosis. There is no blood test, brain scan, or computer task that confirms it on its own. A proper evaluation includes a full developmental and psychiatric history, validated rating scales completed by you and ideally by a partner or family member who knew you in childhood, screening for the conditions that commonly mimic ADHD (sleep disorders, untreated mood or anxiety disorders, trauma, thyroid problems, substance use), and a review of any prior records. Computerized attention tasks can add information but should not replace the clinical interview.

No. Medication is the most effective single intervention for adult ADHD, but it works best alongside structure: sleep, exercise, a workable system for tasks and time, and treatment of co-occurring conditions. Some people do well on non-stimulant medications (atomoxetine, guanfacine, bupropion) when stimulants are not a fit. Cognitive behavioral therapy designed specifically for ADHD also has good evidence and pairs well with medication.

Stimulants are Schedule II controlled substances. During the COVID-19 public health emergency, DEA flexibilities allowed full telehealth prescribing of controlled substances without an initial in-person visit. Those flexibilities are currently extended through December 31, 2026, and the rule may change after that. The Cognia model is built so that ongoing stimulant care does not depend on the flexibility staying in place; if the rule tightens, established patients continue, and any change to evaluation logistics is communicated directly.

ADHD is one of the conditions Cognia treats most often. The first visit is a full 60 to 90 minute evaluation that takes the developmental, sleep, mood, and substance-use history seriously before any medication conversation. When medication is appropriate, the goal is the lowest effective dose that improves function, with attention to sleep, appetite, mood, and cardiovascular vitals. Visit cadence is matched to the clinical picture, not to a fixed schedule.